Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies

<p>Abstract</p> <p>Background</p> <p>Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic c...

Full description

Bibliographic Details
Main Authors: Weissenstein Ulrike, Schumann Agnes, Reif Marcus, Link Susanne, Toffol-Schmidt Ulrike D, Heusser Peter
Format: Article
Language:English
Published: BMC 2012-05-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/12/206
_version_ 1818143810059763712
author Weissenstein Ulrike
Schumann Agnes
Reif Marcus
Link Susanne
Toffol-Schmidt Ulrike D
Heusser Peter
author_facet Weissenstein Ulrike
Schumann Agnes
Reif Marcus
Link Susanne
Toffol-Schmidt Ulrike D
Heusser Peter
author_sort Weissenstein Ulrike
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation with the aim to improve CTC detection with low target antigen densities.</p> <p>Methods</p> <p>Blood samples of healthy donors spiked with breast cancer cell line HCC1937 were used to determine accuracy and precision of the method. 10 healthy subjects were examined to evaluate specificity. CTC counts in 59 patients with MBC were measured to evaluate the prognostic value on overall survival.</p> <p>Results</p> <p>Regression analysis of numbers of recovered vs. spiked HCC1937 cells yielded a coefficient of determination of R<sup>2</sup> = 0.957. The average percentage of cell recovery was 84%. The average within-run coefficient of variation for spiking of 185, 85 and 30 cells was 14%. For spiking of 10 cells the within-run CV was 30%. No CTCs were detected in blood of 10 healthy subjects examined.</p> <p>A standard threshold of 5 CTC/7.5 ml blood as a cut-off point between risk groups led to a highly significant prognostic marker (p < 0.001). To assess the prognostic value of medium CTC levels we additionally considered a low (CTC-L: 0 CTC), a medium (CTC-M: 1–4 CTC) and a high risk group (CTC-H: ≥5 CTC). The effect of this CTC-LMH marker on overall survival was significant as well (p < 0.001). A log-ratio test performed to compare the model with 3 vs. the model with 2 risk groups rejected the model with 2 risk groups (p = 0.026). For CTC as a count variable, we propose an offset reciprocal transformation 1/(1 + x) for overall survival prediction (p < 0.001).</p> <p>Conclusions</p> <p>We show that our CTC detection method is feasible and leads to accurate and reliable results. Our data suggest that a refined differentiation between patients with different CTC levels is reasonable.</p>
first_indexed 2024-12-11T11:37:35Z
format Article
id doaj.art-d8fc7d2061424e74aeb8d144b382037a
institution Directory Open Access Journal
issn 1471-2407
language English
last_indexed 2024-12-11T11:37:35Z
publishDate 2012-05-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj.art-d8fc7d2061424e74aeb8d144b382037a2022-12-22T01:08:43ZengBMCBMC Cancer1471-24072012-05-0112120610.1186/1471-2407-12-206Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodiesWeissenstein UlrikeSchumann AgnesReif MarcusLink SusanneToffol-Schmidt Ulrike DHeusser Peter<p>Abstract</p> <p>Background</p> <p>Circulating tumor cells (CTCs) are detectable in peripheral blood of metastatic breast cancer patients (MBC). In this paper we evaluate a new CTC separation method based on a combination of anti-EpCAM- and anti-cytokeratin magnetic cell separation with the aim to improve CTC detection with low target antigen densities.</p> <p>Methods</p> <p>Blood samples of healthy donors spiked with breast cancer cell line HCC1937 were used to determine accuracy and precision of the method. 10 healthy subjects were examined to evaluate specificity. CTC counts in 59 patients with MBC were measured to evaluate the prognostic value on overall survival.</p> <p>Results</p> <p>Regression analysis of numbers of recovered vs. spiked HCC1937 cells yielded a coefficient of determination of R<sup>2</sup> = 0.957. The average percentage of cell recovery was 84%. The average within-run coefficient of variation for spiking of 185, 85 and 30 cells was 14%. For spiking of 10 cells the within-run CV was 30%. No CTCs were detected in blood of 10 healthy subjects examined.</p> <p>A standard threshold of 5 CTC/7.5 ml blood as a cut-off point between risk groups led to a highly significant prognostic marker (p < 0.001). To assess the prognostic value of medium CTC levels we additionally considered a low (CTC-L: 0 CTC), a medium (CTC-M: 1–4 CTC) and a high risk group (CTC-H: ≥5 CTC). The effect of this CTC-LMH marker on overall survival was significant as well (p < 0.001). A log-ratio test performed to compare the model with 3 vs. the model with 2 risk groups rejected the model with 2 risk groups (p = 0.026). For CTC as a count variable, we propose an offset reciprocal transformation 1/(1 + x) for overall survival prediction (p < 0.001).</p> <p>Conclusions</p> <p>We show that our CTC detection method is feasible and leads to accurate and reliable results. Our data suggest that a refined differentiation between patients with different CTC levels is reasonable.</p>http://www.biomedcentral.com/1471-2407/12/206
spellingShingle Weissenstein Ulrike
Schumann Agnes
Reif Marcus
Link Susanne
Toffol-Schmidt Ulrike D
Heusser Peter
Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
BMC Cancer
title Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
title_full Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
title_fullStr Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
title_full_unstemmed Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
title_short Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies
title_sort detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and epcam antibodies
url http://www.biomedcentral.com/1471-2407/12/206
work_keys_str_mv AT weissensteinulrike detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies
AT schumannagnes detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies
AT reifmarcus detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies
AT linksusanne detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies
AT toffolschmidtulriked detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies
AT heusserpeter detectionofcirculatingtumorcellsinbloodofmetastaticbreastcancerpatientsusingacombinationofcytokeratinandepcamantibodies